News & Updates

Dietary niacin intake may benefit individuals with nonalcoholic fatty liver disease (NAFLD), with a study suggesting that a higher intake lowers the risk of mortality.

In the EMERALD-1 trial, durvalumab plus bevacizumab (D+B) combined with transarterial chemoembolization (TACE) improved progression-free survival (PFS) in individuals with unresectable hepatocellular carcinoma (HCC) eligible for embolization.

Treatment with larsucosterol is safe and well tolerated in patients with alcohol-associated hepatitis (AH), as shown in a recent study.

Noncontrast-enhanced magnetic resonance imaging (NCEMRI) demonstrates superiority over ultrasonography (US) for the surveillance of hepatocellular carcinoma (HCC) in at-risk populations, although this strategy is more expensive than US, according to a Singapore study.

The University of Hong Kong’s (HKU) hepatitis C virus (HCV) microelimination programme targeting high-risk populations is expanded recently to eligible persons in custody (PICs) following initial success in individuals with history of illicit drug use, needle sharing or imprisonment undergoing rehabilitation in halfway houses or drug rehabilitation centres.

Patients with liver disease develop antibodies and T-cell responses following three shots of COVID-19 vaccines, while those who have been infected with SARS-CoV-2 develop mild symptoms only, reports a recent study.

A novel risk score, PAGED-B, may be used to predict hepatocellular carcinoma (HCC) development at the time of transition into hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB), suggests a study.